| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2000 American Heart Association, Inc.
Thrombosis |
Plasma Levels of Tissue Plasminogen Activator/Plasminogen Activator Inhibitor-1 Complex and von Willebrand Factor Are Significant Risk Markers for Recurrent Myocardial Infarction in the Stockholm Heart Epidemiology Program (SHEEP) Study
From the Department of Clinical Chemistry (B.W.) and the Division of Cardiovascular Medicine (U.d.F.), Karolinska Hospital; the Department of Epidemiology (T.A., C.R., A.A.) and Cardivascular Epidemiology (U.d.F.), Institute of Environmental Medicine; and the Division of Social Medicine (J.H.), Department of Public Health Sciences, Karolinska Institute, Stockholm, Sweden.
Correspondence to Prof Björn Wiman, Department of Clinical Chemistry, Karolinska Hospital, S-171 76 Stockholm, Sweden. E-mail bjorn.wiman{at}lab.ks.se
Abstract—An impaired fibrinolytic
function due to elevated plasma levels of plasminogen
activator inhibitor (PAI)-1 activity or tissue
plasminogen activator (tPA) antigen is
correlated with the development of myocardial infarction (MI) in
patients with manifest coronary heart disease. Recently,
methods for determining the specific tPA/inhibitor
complexes constituting tPA antigen in plasma have become available. In
the Stockholm Heart Epidemiology Program
(SHEEP) study, 86 of 1212 MI patients, subjected to blood sampling in a
metabolically stable period, suffered reinfarction before
the end of 1996. These individuals have been compared with an
approximately equal number of matched MI patients without
recurrence and a group of matched healthy control subjects
regarding the plasma concentrations of some hemostatic factors. The
hemostatic compounds studied (fibrinogen, von Willebrand
factor, tPA antigen, PAI-1, and the tPA/PAI-1 complex) were typically
higher in the groups (men and women) with recurrence of MI
compared with those without. The plasma concentrations were also
typically higher in the pooled groups of patients compared with the
groups of healthy control subjects. The largest between-group
differences were found for the plasma tPA/PAI-1 complex. The crude odds
ratio for reinfarction associated with higher concentration (
75th
percentile among the control subjects) of tPA/PAI-1 was 1.8 (95% CI
1.1 to 3.1); the corresponding crude odds ratio for von
Willebrand factor was 2.3 (1.3 to 4.0). The tPA/PAI-1 complex
correlated strongly with PAI-1 and tPA antigen in all groups and with
serum triglycerides and body mass index in all groups
except for women with reinfarction. An increased plasma level of
tPA/PAI-1 complex is a novel risk marker for recurrent MI in men and
women. Most likely, increased plasma levels of tPA/PAI-1 complex
reflect impaired fibrinolysis, because the correlation
with PAI-1 is strong. Further support is obtained indicating that the
plasma concentration of von Willebrand factor is also an
important risk marker for recurrent MI.
Key Words: fibrinolysis • hemostasis • myocardial infarction • risk markers
This article has been cited by other articles:
 |
|
 |
|
  I. Janszky, J. Hallqvist, T. Tomson, A. Ahlbom, K. J. Mukamal, and S. Ahnve Increased risk and worse prognosis of myocardial infarction in patients with prior hospitalization for epilepsy--The Stockholm Heart Epidemiology Program Brain, October 1, 2009; 132(10): 2798 - 2804. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Zhao, X. Ma, X. Xie, and G. X. Shen Involvement of NADPH oxidase in oxidized LDL-induced upregulation of heat shock factor-1 and plasminogen activator inhibitor-1 in vascular endothelial cells Am J Physiol Endocrinol Metab, July 1, 2009; 297(1): E104 - E111. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Mouquet, F. Cuilleret, S. Susen, K. Sautiere, P. Marboeuf, P. V. Ennezat, E. McFadden, P. Pigny, F. Richard, B. Hennache, et al. Metabolic syndrome and collateral vessel formation in patients with documented occluded coronary arteries: association with hyperglycaemia, insulin-resistance, adiponectin and plasminogen activator inhibitor-1 Eur. Heart J., April 1, 2009; 30(7): 840 - 849. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Suzuki, H. Mogami, H. Ihara, and T. Urano Unique secretory dynamics of tissue plasminogen activator and its modulation by plasminogen activator inhibitor-1 in vascular endothelial cells Blood, January 8, 2009; 113(2): 470 - 478. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. R. Hajer, T. W. van Haeften, and F. L.J. Visseren Adipose tissue dysfunction in obesity, diabetes, and vascular diseases Eur. Heart J., December 2, 2008; 29(24): 2959 - 2971. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Yano, T. Ohmori, S. Hoshide, S. Madoiwa, K. Yamamoto, T. Katsuki, T. Mitsuhashi, J. Mimuro, K. Shimada, K. Kario, et al. Determinants of thrombin generation, fibrinolytic activity, and endothelial dysfunction in patients on dual antiplatelet therapy: involvement of factors other than platelet aggregability in Virchow's triad Eur. Heart J., July 2, 2008; 29(14): 1729 - 1738. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. O. Spiel, J. C. Gilbert, and B. Jilma Von Willebrand Factor in Cardiovascular Disease: Focus on Acute Coronary Syndromes Circulation, March 18, 2008; 117(11): 1449 - 1459. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Raff, T. Tholstrup, S. Basu, P. Nonboe, M. T. Sorensen, and E. M. Straarup A Diet Rich in Conjugated Linoleic Acid and Butter Increases Lipid Peroxidation but Does Not Affect Atherosclerotic, Inflammatory, or Diabetic Risk Markers in Healthy Young Men J. Nutr., March 1, 2008; 138(3): 509 - 514. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Janszky, R. Ljung, S. Ahnve, J. Hallqvist, A. M. Bennet, and K. J. Mukamal Alcohol and long-term prognosis after a first acute myocardial infarction: the SHEEP study Eur. Heart J., January 1, 2008; 29(1): 45 - 53. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Tkac, S. F. P. Man, and D. D. Sin Review: Systemic consequences of COPD Therapeutic Advances in Respiratory Disease, October 1, 2007; 1(1): 47 - 59. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Zhao and G. X. Shen Involvement of Heat Shock Factor-1 in Glycated LDL-Induced Upregulation of Plasminogen Activator Inhibitor-1 in Vascular Endothelial Cells Diabetes, May 1, 2007; 56(5): 1436 - 1444. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A.M.A. Thijssen, G. Hornstra, and R. P. Mensink Stearic, Oleic, and Linoleic Acids Have Comparable Effects on Markers of Thrombotic Tendency in Healthy Human Subjects J. Nutr., December 1, 2005; 135(12): 2805 - 2811. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Stuveling, S. J. L. Bakker, H. L. Hillege, P. E. de Jong, R. O. B. Gans, and D. de Zeeuw Biochemical risk markers: a novel area for better prediction of renal risk? Nephrol. Dial. Transplant., March 1, 2005; 20(3): 497 - 508. [Full Text] [PDF]
|
|
|
|
 |
|
 E.-G. V. Giardina, H. J. Chen, R. R. Sciacca, and L. E. Rabbani Dynamic Variability of Hemostatic and Fibrinolytic Factors in Young Women J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6179 - 6184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G.D.O. Lowe, J. Danesh, S. Lewington, M. Walker, L. Lennon, A. Thomson, A. Rumley, and P.H. Whincup Tissue plasminogen activator antigen and coronary heart disease: Prospective study and meta-analysis Eur. Heart J., February 1, 2004; 25(3): 252 - 259. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Takeshita, M. Hayashi, S. Iino, T. Kondo, Y. Inden, M. Iwase, T. Kojima, M. Hirai, M. Ito, D. J. Loskutoff, et al. Increased Expression of Plasminogen Activator Inhibitor-1 in Cardiomyocytes Contributes to Cardiac Fibrosis after Myocardial Infarction Am. J. Pathol., February 1, 2004; 164(2): 449 - 456. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sowers, C. Derby, M. L. Jannausch, J. I. Torrens, and R. Pasternak Insulin Resistance, Hemostatic Factors, and Hormone Interactions in Pre- and Perimenopausal Women: SWAN J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4904 - 4910. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Holmquist, S. Larsson, A. Wolk, and U. de Faire Multivitamin Supplements Are Inversely Associated with Risk of Myocardial Infarction in Men and Women--Stockholm Heart Epidemiology Program (SHEEP) J. Nutr., August 1, 2003; 133(8): 2650 - 2654. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.H. Whincup, J. Danesh, M. Walker, L. Lennon, A. Thomson, P. Appleby, A. Rumley, and G.D.O. Lowe von Willebrand factor and coronary heart disease. Prospective study and meta-analysis Eur. Heart J., November 2, 2002; 23(22): 1764 - 1770. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Karnicki, W. G. Owen, R. S. Miller, and R. D. McBane II Factors Contributing to Individual Propensity for Arterial Thrombosis Arterioscler Thromb Vasc Biol, September 1, 2002; 22(9): 1495 - 1499. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Mills, M. W. Mansfield, and P. J. Grant Tissue Plasminogen Activator, Fibrin D-Dimer, and Insulin Resistance in the Relatives of Patients With Premature Coronary Artery Disease Arterioscler Thromb Vasc Biol, April 1, 2002; 22(4): 704 - 709. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Edelberg, P. D. Christie, and R. D. Rosenberg Regulation of Vascular Bed-Specific Prothrombotic Potential Circ. Res., July 20, 2001; 89(2): 117 - 124. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Bounameaux and E. K. O. Kruithof On the Association of Elevated tPA/PAI-1 Complex and von Willebrand Factor With Recurrent Myocardial Infarction Arterioscler Thromb Vasc Biol, August 1, 2000; 20(8): 1857 - 1859. [Full Text] [PDF]
|
|
|
|
|
|
J. D. Mills, M. W. Mansfield, and P. J. Grant Tissue Plasminogen Activator, Fibrin D-Dimer, and Insulin Resistance in the Relatives of Patients With Premature Coronary Artery Disease Arterioscler Thromb Vasc Biol, April 1, 2002; 22(4): 704 - 709. [Abstract] [Full Text] [PDF]
|
|